

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM805868

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ACELRX PHARMACEUTICALS, INC.		04/03/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	VERTICAL PHARMACEUTICALS, LLC		
Street Address:	1880 MCFARLAND PARKWAY, SUITE 110		
City:	ALPHARETTA		
State/Country:	GEORGIA		
Postal Code:	30005		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	5781956	DSUVIA	
CORRESPONDENCE DATA			
Fax Number:	8032559831		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	8643732260		
Email:	IPdocket@nelsonmullins.com, elaine.stephenson@nelsonmullins.com		
Correspondent Name:	Neil C. Jones		
Address Line 1:	Nelson Mullins Riley & Scarborough LLP		
Address Line 2:	301 SOUTH COLLEGE STREET, SUITE 2300		
Address Line 4:	Charlotte, NORTH CAROLINA 28202		
NAME OF SUBMITTER:	Neil C. Jones, SC Bar No. 062911		
SIGNATURE:	/Neil C. Jones/		
DATE SIGNED:	04/25/2023		
Total Attachments: 14			
source=AcelRx - Vertical IP Assignment Agreement (Executed)#page1.tif			
source=AcelRx - Vertical IP Assignment Agreement (Executed)#page2.tif			
source=AcelRx - Vertical IP Assignment Agreement (Executed)#page3.tif			
source=AcelRx - Vertical IP Assignment Agreement (Executed)#page4.tif			

OP \$40.00 5781956

source=AceIRx - Vertical IP Assignment Agreement (Executed)#page5.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page6.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page7.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page8.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page9.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page10.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page11.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page12.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page13.tif
source=AceIRx - Vertical IP Assignment Agreement (Executed)#page14.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (this “**IP Assignment Agreement**”) is made as of April 3, 2023 by and between AcelRx Pharmaceuticals, Inc., a Delaware corporation (“**Seller**”), and Vertical Pharmaceuticals, LLC, a Delaware limited liability company (“**Buyer**” and, together with Seller, collectively the “**Parties**” and each, a “**Party**”). Unless otherwise defined, all capitalized terms in this IP Assignment Agreement have the meanings ascribed to them in the Agreement (as defined below).

RECITAL

Seller and Buyer are parties to an Asset Purchase Agreement dated March 12, 2023 (the “**Agreement**”), pursuant to which Seller agreed to sell, and Buyer agreed to purchase and assume from Seller, certain assets and liabilities related to the Program, including the Transferred Intellectual Property and the Regulatory Materials.

The Parties desire to carry out the intent and purpose of the Agreement by the execution and delivery of this instrument evidencing the vesting in Buyer of all right, title and interest in, to and under the Transferred Intellectual Property.

AGREEMENTS

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows:

Section 1. Transfer and Assignment of the Transferred Intellectual Property. Seller hereby sells, conveys, transfers, assigns and delivers to Buyer, and Buyer hereby purchases, acquires and accepts from Seller, all of the right, title and interest of Seller in, to and under the Transferred Intellectual Property, free and clear of all Encumbrances other than Permitted Encumbrances, including the following: (a) all patents and patent applications listed on Exhibit A, any and all inventions described by, embodied in, and/or claimed by such patents and patent applications, and any substitute applications which may be filed upon any such inventions; (b) any and all renewals, divisionals, continuations and continuations-in-part of the patents and patent applications listed on Exhibit A; (c) any patent applications claiming direct or indirect priority to any of the foregoing; (d) all foreign patent applications associated with and/or claiming priority to the patent applications referenced in the preceding clauses (a)-(c); (e) all patents issued or issuing from the patent applications referenced in the preceding clauses (a)-(d); (f) all reissues, reexaminations, restorations (including supplemental protection certificates) and extensions of any patent or patent application referenced in the preceding clauses (a)-(e); (g) the right to file for any patent applications in the United States or in foreign countries for the inventions references in preceding clause (a); (h) all trademark registrations and applications listed on Exhibit B; (i) all common law or other rights in any trademarks, trade dress, or other identifying indicia associated with the Product that are necessary for, or are used by Seller as of the Effective Date in connection with, the Development, manufacture (including synthesis, formulation, finishing or packaging), use, holding, marketing, offer for sale, sale, distribution, export or import of any Product; (j) Seller’s right to sue and collect damages for past, present and future infringement, dilution, misappropriation, unauthorized use and/or any other violation of

the Transferred Intellectual Property; and (k) all income, royalties, damages or payments due on or after the Closing Date relating to, or resulting from the licensing or enforcement of, the Transferred Intellectual Property (except with respect to Seller's rights under the Transferred Intellectual Property granted by Buyer pursuant to the Intellectual Property Agreement between the Parties entered into in connection with the Agreement). Seller hereby authorizes and requests the issuing authority of any patent, trademark, or other intellectual property protection to issue any and all patents, trademark, or other intellectual property certificates with respect to the Transferred Intellectual Property to Buyer as assignee of the entire interest therein.

Section 2. Trademark Rights. With respect to the transfer of any trademarks that are Transferred Intellectual Property, Seller hereby sells, conveys, transfers, assigns and delivers to Buyer all goodwill associated with and symbolized by such trademarks.

Section 3. Further Assurances. Each Party covenants that at any time, and from time to time, after the Closing Date, but subject to the express provisions of the Agreement and without expanding any Party's express obligations thereunder, it will execute, at the executing Party's own cost, such additional instruments and take such actions as may be reasonably requested by the other Party to effectuate Seller's sale and assignment of the Transferred Intellectual Property to Buyer, vest title to the Transferred Intellectual Property in Buyer, and otherwise carry out the intent and purposes of this IP Assignment Agreement, including, but not limited to, Seller executing the necessary documents to transfer rights in any Madrid Protocol trademarks to Buyer.

Section 4. Relation to Agreement. This IP Assignment Agreement is executed and delivered pursuant to and subject to the Agreement (including, without limitation, the representations, warranties, covenants, indemnities and agreements contained therein), which is incorporated herein by reference. In the event of a conflict between the terms and conditions of this IP Assignment Agreement and the terms and conditions of the Agreement, the terms and conditions of the Agreement shall govern, supersede, and prevail. Notwithstanding anything to the contrary in this IP Assignment Agreement, nothing in this IP Assignment Agreement shall (and is not intended to) be deemed to defeat, limit, reduce, alter, impair, enhance, enlarge, or supersede any right, obligation, liability, claim, or remedy created by the Agreement or any Ancillary Agreement. The provisions of this IP Assignment Agreement shall not merge in or be superseded by and shall survive (to the extent provided for in the Agreement) the completion of the transactions provided for in the Agreement or any Ancillary Agreement.

Section 5. Counterparts; Facsimile; Electronic Mail. This IP Assignment Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this IP Assignment Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. The exchange of copies of this IP Assignment Agreement and of signature pages by facsimile, pdf format, docusign or electronic mail transmission shall constitute effective execution and delivery of this IP Assignment Agreement as to the Parties and may be used in lieu of the original IP Assignment Agreement for all purposes. Signatures of the Parties transmitted by facsimile or electronic mail shall be deemed to be their original signatures for all purposes.

Section 6. Governing Law. Section 10.9 (Governing Law) of the Agreement shall also apply with respect to this IP Assignment Agreement, *mutatis mutandis*.

Section 7. Amendments; Waivers. This IP Assignment Agreement may only be amended by a writing signed by the Parties. Any waiver of rights hereunder must be set forth in writing. A waiver of any breach or failure to enforce any of the terms or conditions of this IP Assignment Agreement shall not in any way affect, limit or waive any Party's rights at any time to enforce strict compliance thereafter with every term or condition of this IP Assignment Agreement.

Section 8. Third Party Beneficiaries and Obligations. This IP Assignment Agreement is for the sole benefit of the Parties and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this IP Assignment Agreement.

Section 9. Notices. Any notice, request, or other document to be given hereunder to any Party shall be given in the manner specified in Section 10.1 (Notices) of the Agreement.

Section 10. Severability. If any term or provision of this IP Assignment Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this IP Assignment Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the Parties shall negotiate in good faith to modify this IP Assignment Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.

Section 11. Entire Agreement. This IP Assignment Agreement, together with the Agreement, Ancillary Agreements, and the other exhibits and documents referred to in the Agreement and the Ancillary Agreements, contain the entire understanding between the Parties with respect to the transactions contemplated hereby and thereby, supersede all prior agreements, understandings, representations and statements, oral or written, between the Parties on the subject matter hereof, which such prior agreements, understandings, representations and statements, oral or written, shall be of no further force or effect.

[Remainder of page intentionally left blank]

Seller and Buyer have executed and delivered this IP Assignment Agreement as of the date set forth above.

SELLER:

AcelRx Pharmaceuticals, Inc.

By: *Vincent J. Angotti*
Name: Vincent J. Angotti
Title: Chief Executive Officer

BUYER:

Vertical Pharmaceuticals, LLC

By: _____
Name:
Title:

Seller and Buyer have executed and delivered this IP Assignment Agreement as of the date set forth above.

SELLER:

AcelRx Pharmaceuticals, Inc.

By: _____
Name: Vincent J. Angotti
Title: Chief Executive Officer

BUYER:

Vertical Pharmaceuticals, LLC


By:  _____
Name: Harold A. Deas, Jr.
Title: Chief Executive Officer

EXHIBIT A
Program Patents

Program Patents

The Parties acknowledge and agree that the following Program Patent schedule has been prepared in good faith and includes all Program Patents that are known and agreed by the Parties as of the Effective Date. In the event that a Party discovers any omitted patent rights owned by Seller and that should have been included in the schedule, the Parties shall discuss such possible omission in good faith and, if mutually agreed, the Parties will add such omitted patent rights to the Program Patent schedule as necessary.

Cooley Docket Number	Application No.	Application Date	Registration No.	Registration Date	Publication No.	Publication Date	Case Status	Country
ACEL-011/01CA	2636088	1/8/2007	2636088	2/21/2017			Issued	Canada
ACEL-011/01CN	200780007142.9	1/8/2007	ZL200780007142.9	12/21/2016	101394863A	3/25/2009	Issued	China
ACEL-011/01MO	J/002536(680)	1/8/2007	J/002536	6/9/2017			Issued	Macau
ACEL-011/01IN	2874/KOLNP/2008	1/8/2007					Pending	India
ACEL-011/01JP	2008-549612	1/8/2007	5183490	1/25/2013	2008-549612	6/11/2009	Issued	Japan
ACEL-011/01KR	2008-7019313	1/8/2007	1503074	3/10/2015			Issued	Republic of Korea
ACEL-011/01US	11/650,174	1/5/2007	8,202,535 ☉	6/19/2012	US 2010-0256190 A1	10/7/2010	Issued	United States of America
ACEL-011/04US	11/974,092	10/11/2007	8,231,900 ☉	7/31/2012	US 2009-0131479 A1	5/21/2009	Issued	United States of America
ACEL-011/10US	13/561,543	7/30/2012	8,778,394 ☉	7/15/2014	US-2013/0165481-A1	6/27/2013	Issued	United States of America
ACEL-011/10EP	20161845.1						Pending	European Patent Office
ACEL-011/14US	14/296,992	6/5/2014	10,342,762 ☉	7/9/2019	US-2014-0350054-A1	11/27/2014	Issued	United States of America
ACEL-011/08CN	201611042683.2	1/8/2007			CN 106727271 A	5/31/2017	Pending	China
ACEL-011/10HK	17112585.7	1/8/2007	1238555	12/18/2020	HK1238555		Pending	Hong Kong
ACEL-011/09AT	16163199.9	1/8/2007	3072504	3/18/2020			Issued	Austria
ACEL-011/09BE	16163199.9	1/8/2007	3072504	3/18/2020			Issued	Belgium
ACEL-011/09CH	16163199.9	1/8/2007	3072504	3/18/2020			Issued	Switzerland
ACEL-011/09DE	16163199.9	1/8/2007	3072504	3/18/2020			Issued	Germany
ACEL-011/09DK	16163199.9	1/8/2007	3072504	3/18/2020			Issued	Denmark
ACEL-011/09EP	16163199.9	1/8/2007	3072504	3/18/2020	3072504	9/28/2016	Issued	European Patent Office
ACEL-011/09ES	16163199.9	1/8/2007	3072504	3/18/2020	3072504		Issued	Spain
ACEL-011/09FR	16163199.9	1/8/2007	3072504	3/18/2020	3072504		Issued	France
ACEL-011/09GB	16163199.9	1/8/2007	3072504	3/18/2020	3072504		Issued	United Kingdom
ACEL-011/09HK	17103097.7	1/8/2007	1238555	2/19/2021	1229247	11/17/2017	Issued	Hong Kong
ACEL-011/09IE	16163199.9	1/8/2007	3072504	3/18/2020	3072504		Issued	Ireland
ACEL-011/09IT	16163199.9	1/8/2007	3072504	3/18/2020	3072504		Issued	Italy
ACEL-011/09NL	16163199.9	1/8/2007	3072504	3/18/2020	3072504		Issued	Netherlands
ACEL-011/09PT	16163199.9	1/8/2007	3072504	3/18/2020	3072504		Issued	Portugal
ACEL-011/09SE	16163199.9	1/8/2007	3072504	3/18/2020	3072504		Issued	Sweden
ACEL-011/09US	13/276,165	10/18/2011	8,535,714	9/17/2013	US-2012-0035216 A1	2/2/2012	Issued	United States of America
ACEL-011/06US	11/985,162	11/14/2007	8,865,743 ☉	10/21/2014	US 2008/0268023 A1	10/30/2008	Issued	United States of America
ACEL-011/16US	14/517,260	10/17/2014	9,320,710 ☉	4/26/2016	US-2015-0105424-A1	4/16/2015	Issued	United States of America

Cooley Docket Number	Application No.	Application Date	Registration No.	Registration Date	Publication No.	Publication Date	Case Status	Country
ACEL-011/17US	15/092,127	4/6/2016	9,744,129 ☉	8/29/2017	US 2016-0213606 A1	7/28/2016	Issued	United States of America
ACEL-011/19US	15/655,316	7/20/2017	10,245,228 ☉	4/2/2019	US 2018-0161270	6/14/2018	Issued	United States of America
ACEL-011/20US	16/153,301	10/5/2018	10,507,180 ☉	12/17/2019	US 2019-0125659	5/2/2019	Issued	United States of America
ACEL-011/06CA	2673856	12/28/2007					Office Action Issued	Canada
ACEL-011/06CH	7870025.9	12/28/2007	2114383	7/21/2010	2114383		Issued	Switzerland
ACEL-011/06CN	200780051982.5	12/28/2007	ZL200780051982.5	6/1/2016	101621994A	1/6/2010	Issued	China
ACEL-011/06MO	J/002305(103)	12/28/2007	J/002305	11/10/2016			Issued	Macau
ACEL-011/06DE	7870025.9	12/28/2007	60 2007 007 991.8-08	7/21/2010	2114383		Issued	Germany
ACEL-011/06DK	7870025.9	12/28/2007	2114383	7/21/2010	2114383		Issued	Denmark
ACEL-011/06EP	7870025.9	12/28/2007	2114383	7/21/2010	2114383	11/11/2009	EP Granted	European Patent Office
ACEL-011/06ES	7870025.9	12/28/2007	2348688	7/21/2010	2114383		Issued	Spain
ACEL-011/06FR	7870025.9	12/28/2007	2114383	7/21/2010	2114383		Issued	France
ACEL-011/06GB	7870025.9	12/28/2007	2114383	7/21/2010	2114383		Issued	United Kingdom
ACEL-011/06IN	2419/KOLNP/2009	12/28/2007	286766	8/29/2017			Issued	India
ACEL-011/06IT	7870025.9	12/28/2007	2114383	7/21/2010	2114383		Issued	Italy
ACEL-011/06KR	2009-7016353	12/28/2007	10-1545754	8/12/2015			Issued	Republic of Korea
ACEL-011/06NL	7870025.9	12/28/2007	2114383	7/21/2010	2114383		Issued	Netherlands
ACEL-011/06PT	7870025.9	12/28/2007	2114383	7/21/2010	2114383		Issued	Portugal
ACEL-011/06SE	7870025.9	12/28/2007	2114383	7/21/2010	2114383		Issued	Sweden
ACEL-011/07US	12/521,949	12/28/2007	8,226,978 ☉	7/24/2012	US 2010-0105735 A1	7/19/2008	Issued	United States of America
ACEL-011/12US	13/555,948	7/23/2012	8,778,393 ☉	7/15/2014	US-2013-0158074-A1	6/20/2013	Issued	United States of America
ACEL-011/09US	13/276,165	10/18/2011	8,535,714 ☉	9/17/2013	US 2012-0035216-A1	2/9/2012	Issued	United States of America
ACEL-010/02US	11/650,227	1/5/2007	8,252,328 ☉	8/28/2012	US 2007-0207207 A1	9/6/2007	Issued	United States of America
ACEL-010/03US	11/825,251	7/3/2007	8,252,329 ☉	8/28/2012	US 2008-0166404 A1	7/10/2008	Issued	United States of America
ACEL-010/04US	13/595,879	8/27/2012	8,865,211 ☉	10/21/2014	US-2013/0156842-A1	6/20/2013	Issued	United States of America
ACEL-004/00AU	2009316874	11/12/2009	2009316874	9/29/2016			Issued	Australia
ACEL-004/00BR	PI 0921519-0	11/12/2009			2421	5/30/2017	Pending	Brazil
ACEL-004/00CA	2743261	11/12/2009	2743261	11/1/2016			Issued	Canada
ACEL-004/00CH	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	Switzerland
ACEL-004/00CN	200980146531.9	11/12/2009	ZL 200980146531.9	7/16/2014	102231980A	11/2/2011	Issued	China
ACEL-004/00DE	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	Germany
ACEL-004/00DK	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	Denmark
ACEL-004/00EP	9760659.4	11/12/2009	2367537	10/17/2012	2367537	9/28/2011	Issued	European Patent Office
ACEL-004/00ES	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	Spain
ACEL-004/00FR	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	France
ACEL-004/00GB	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	United Kingdom
ACEL-004/00IL	212880	11/12/2009	212880	12/1/2015		1/31/2013	Issued	Israel

Cooley Docket Number	Application No.	Application Date	Registration No.	Registration Date	Publication No.	Publication Date	Case Status	Country
ACEL-004/00IN	4618/DELNP/2011	11/12/2009					Pending	India
ACEL-004/00IT	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	Italy
ACEL-004/00KR	10-2011-7014296	11/12/2009					Pending	Republic of Korea
ACEL-004/00MX	MX/a/2011/005370	11/12/2009	302647	8/23/2012			Issued	Mexico
ACEL-004/00NL	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	Netherlands
ACEL-004/00NZ	593512	11/12/2009	593512	3/22/2013			Issued	New Zealand
ACEL-004/00PT	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	Portugal
ACEL-004/00RU	2011125316	11/12/2009	2530579	10/10/2014	n/a	12/27/2012	Issued	Russian Federation
ACEL-004/00SE	9760659.4	11/12/2009	2367537	10/17/2012	2367537		Issued	Sweden
ACEL-004/00SG	201103689-4	11/12/2009	171786	12/31/2013			Issued	Singapore
ACEL-004/00US	12/275,485	11/21/2008	8,945,592 ☞	2/3/2015	US 2010/0130551 A1	5/27/2010	Issued	United States of America
ACEL-003/01US	12/724,634	3/16/2010	8,548,623	10/1/2013	US-2010/0253476 A1	10/7/2010	Issued	United States of America
ACEL-003/02US	13/416,236	3/9/2012	8,574,189 ☞	11/5/2013	US-2012/0232473 A1	9/13/2012	Issued	United States of America
ACEL-003/05US	16/143,046	9/26/2018	10,896,751	1/19/2021	US-2019/0027241	1/24/2019	Issued	United States of America
ACEL-003/06US	17/150,450	1/15/2021			US-2021-0151153 A1	5/20/2021	Allowed	United States of America
ACEL-012/01AU	2015369710	12/22/2015	2015369710A	1/7/2021		6/30/2016	Issued	Australia
ACEL-012/01BR	112017013311-3	12/22/2015	112017013311-3	5/31/2022	112017013311-3	1/9/2018	Issued	Brazil
ACEL-012/01MY	2017000907	12/22/2015	187877A	10/26/2021		6/30/2016	Issued	Malaysia
ACEL-012/01NZ	732808	12/22/2015	732808A	3/25/2022		6/30/2016	Issued	New Zealand
ACEL-012/01SG	11201704797	12/22/2015	11201704797T	2/4/2021		6/30/2016	Issued	Singapore
ACEL-012/01TH	1701003575	12/22/2015			177543	7/5/2018		Thailand
ACEL-012/01US	14/978,634	12/22/2015	11,058,856	7/13/2021	US-2016/0175533	6/23/2016	Issued	United States of America
ACEL-013/01AT	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Austria
ACEL-013/01BE	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Belgium
ACEL-013/01CH	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Switzerland
ACEL-013/01CN	201680069735.7a	10/28/2016	ZL201680069735.7	4/16/2021	108367105	8/3/2018	Issued	China
ACEL-013/01DE	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Germany
ACEL-013/01DK	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Denmark
ACEL-013/01EP	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	European Patent Office
ACEL-013/01ES	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Spain
ACEL-013/01FR	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	France
ACEL-013/01GB	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	United Kingdom
ACEL-013/01HK	16861005.3	10/28/2016	1260615A	2/19/2021	1260615	12/20/2019	Issued	Hong Kong
ACEL-013/01IE	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Ireland
ACEL-013/01IT	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Italy
ACEL-013/01NL	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Netherlands
ACEL-013/01PT	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Portugal
ACEL-013/01SE	16861005.3	10/28/2016	3368097A	3/18/2020			Issued	Sweden
ACEL-013/01US	15/965,285	4/27/2018			US-2018/0243169	8/30/2018	Pending	United States of America
ACEL-013/02CN	202110332182.2a	10/28/2016			113143769	7/23/2021	Pending	China
ACEL-013/02EP	20156766.6a	10/28/2016			3682915	7/22/2020	Pending	European Patent Office
ACEL-013/02HK	42020022645.4a	10/28/2016			40032805	4/1/2021	Pending	Hong Kong
ACEL-013/02HK	42021037695.0a	10/28/2016			40048283	12/3/2021	Pending	Hong Kong
ACEL-013/03EP		3/XX/2023					Filed	European Patent Office

EXHIBIT B

Marks

Marks

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	MADRID PROTOCOL DATE	HISTORY AND STATUS
DSUVIA	United States	Application No. 86850846 Registration No. 5781956		Filed: Dec-16-2015 Registered: Jun-18-2019
DZUVEO	Argentina	Application No. 3704010 Registration No. 3017277		Filed: Apr-25-2018 Registered: Sep-10-2019
DZUVEO	Argentina	Application No. 3704009 Registration No. 3058988		Filed: Apr-25-2018 Registered: Feb-10-2020
DSUVIA	Australia (via Madrid Protocol)	Application No. 1793723 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Jan-10- 2017
DSUVIA	Brazil	Application No. 911184554 Registration No. 911184554		Filed: Jun-15-2016 Registered: Jul-03-2018
DSUVIA (refile)	Canada	Application No. 2081545		Filed: Feb-02-2021
DZUVEO	Canada	Application No. 1894912 Registration No. TMA1077512		Filed: Apr-20-2018 Registered: Oct-06-2020
DSUVIA	China (via Madrid Protocol)	Application No. Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Oct-24- 2017
DSUVIA	European Union	Application No. 1307686 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Feb-03- 2017
DZUVEO	European	Application No.		Filed: Jul-06-2017

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	MADRID PROTOCOL DATE	HISTORY AND STATUS
	Union	016956153 Registration No. 016956153		Registered: Nov-03-2017
DSUVIA	Hong Kong	Application No. 303806839 Registration No. 303806839		Filed: Jun-15-2016 Registered: Jan-17-2017
DSUVIA	India (via Madrid Protocol)	Application No. 3393174 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Apr-12- 2018
DSUVIA	Israel (via Madrid Protocol)	Application No. 1307686 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Feb-04- 2018
DSUVIA	Japan (via Madrid Protocol)	Application No. 1307686 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Jan-27- 2017
DSUVIA	Madrid Protocol Designated Jurisdictions Australia, China, European Union, India, Israel, Japan, Mexico, New Zealand, Norway, Russia, Singapore, South Korea, Switzerland, and Turkey	Application No. 1307686 Registration No. 1307686		Filed: Jun-14-2016 Registered: Sep-01- 2016
DSUVIA	Mexico (via Madrid	Application No. 1792141	Jun-14-2016	Filed: Jun-14-2016 Registered: Mar-02-

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	MADRID PROTOCOL DATE	HISTORY AND STATUS
	Protocol)	Registration No. 1854198		2018
DSUVIA	Mexico (via Madrid Protocol)	Application No. 1792140 Still pending	Jun-14-2016	Filed: Jun-14-2016 Abandoned
DSUVIA	New Zealand (via Madrid Protocol)	Application No. 1050066 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Jan-05- 2017
DSUVIA	Norway (via Madrid Protocol)	Application No. 1307686 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Feb-24- 2017
DSUVIA	Russia (via Madrid Protocol)	Application No. 1307686 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Dec-11- 2017
DSUVIA	Singapore (via Madrid Protocol)	Application No. 40201614458U Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Dec-15- 2016
DSUVIA	South Africa	Application No. 201616305 Registration No. 201616305		Filed: Jun-15-2016 Registered: Jun-28-2018
DSUVIA	South Korea (via Madrid Protocol)	Application No. 1307686 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Apr-04- 2017
DSUVIA	Switzerland (via Madrid Protocol)	Application No. 1307686 Registration No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Jun-21- 2017
DSUVIA	Taiwan	Application No. 105034420 Registration No. 1814805		Filed: Jun-15-2016 Registered: Jan-01-2017
DSUVIA	Turkey (via Madrid	Application No. 1307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Nov-05-

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	MADRID PROTOCOL DATE	HISTORY AND STATUS
	Protocol)	Registration No. 1307686		2018
DSUVIA	United Kingdom (via Madrid Protocol)	Application No. 1307686 Registration No. UK00801307686	Jun-14-2016	Filed: Jun-14-2016 Registered: Feb-03- 2017
DZUVEO	United Kingdom	Application No. 016956153 Registration No. UK00916956153		Filed: Jul-06-2017 Registered: Nov-03-2017